# OnCo record sjmb12 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sjmb12/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sjmb12", "NCT01878617" ;
  schema:name "SJMB12"@en ;
  schema:alternateName "St. Jude SJMB12"@en ;
  schema:description "SJMB12 is the St. Jude trial that first treated medulloblastoma by its molecular type: children with the low-risk WNT form receive a much lower dose of radiotherapy to the brain and spine, those with the SHH form add the targeted drug vismodegib, and the others add two extra chemotherapy drugs; it is still running and the corpus records the design."@en ;
  schema:url <https://onco.cc/trials/sjmb12/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01878617> ;
  onco:status "active" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/medulloblastoma-wnt/>, <https://onco.cc/cancers/medulloblastoma-shh/>, <https://onco.cc/cancers/medulloblastoma-group-3-4/>, <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/brain-tumours/>, <https://onco.cc/cancers/childhood-cancers/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/vismodegib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:institutions <https://onco.cc/institutions/st-jude/> .